https://www.thebodypro.com/author/gerald-pierone-jr

Latest by Gerald Pierone Jr., M.D.

Conference Coverage

The Once and Future King: What Will Replace Atripla Atop the First-Line HIV Treatment Realm?

Gerald Pierone Jr., M.D. Atripla (which is a combination of efavirenz + tenofovir + emtricitabine) is the acknowledged king in the realm of first-line antiretroviral therapy.  Le Roi est mort, vive le Roi!  Not so fast: The king still breathes. But ...

Conference Coverage

The End of HIV Drug Development as We Know It?

Gerald Pierone Jr., M.D. While scanning the CROI 2010 abstracts during my six-hour plane ride to San Francisco, the thought occurred to me that we may be witnessing the winding down of the HIV drug development process. Historically, CROI has been a...

Conference Coverage

Switching Protease Inhibitors Does Not Compromise Efficacy, Safety, Study Suggests

This is Gerald Pierone from the AIDS Research and Treatment Center of the Treasure Coast. I'm here in Mexico City at the International AIDS Conference with Dr. Ben Young, and we're at a poster presentation. The title of the poster is "Switching to Fo...

Presence of Binding Antibodies in Genital Secretions of High-Risk, HIV-Uninfected Women Offers Possible Explanation of "HIV Immunity" Enigma

There's nothing like hearing the results of studies directly from those who actually conducted the research. It is these women and men who are transforming HIV treatment and care. In this interview, you'll meet one of these impressive HIV researchers...

Bone

Bone Loss Similar Among Patients Taking Lopinavir/Ritonavir or Efavirenz; Race, Baseline CD4 May Play Role

There's nothing like hearing the results of studies directly from those who actually conducted the research. It is these women and men who are transforming HIV treatment and care. In this interview, you'll meet one of these impressive HIV researchers...

Atazanavir Noninferior to Lopinavir in Treatment-Naive HIV-Infected People

Although atazanavir, also known as Reyataz, is not uncommonly used in first-line patients, it is not officially approved by the U.S. Food and Drug Administration \[FDA\] for such use. In a large study presented at CROI 2008, atazanavir was compared w...

Interleukin-2 Ineffective in Maintaining Baseline CD4+ Cell Count During Treatment Interruption

There's nothing like hearing the results of studies directly from those who actually conducted the research. It is these women and men who are transforming HIV treatment and care. In this interview, you'll meet one of these impressive HIV researchers...

Liver

Non-Alcoholic Fatty Liver Disease Is Common in HAART-Experienced Patients; Several HIV- and Antiretroviral-Related Factors May Play Role

There's nothing like hearing the results of studies directly from those who actually conducted the research. It is these women and men who are transforming HIV treatment and care. In this interview, you'll meet one of these impressive HIV researchers...

Elite Controllers May Experience Higher Immune Activation Levels Than Other HIV-Infected Patients, Spurring Concerns of CD4+ Decline

There's nothing like hearing the results of studies directly from those who actually conducted the research. It is these women and men who are transforming HIV treatment and care. In this interview, you'll meet one of these impressive HIV researchers...

Unique, Statewide Program of Acute HIV Testing and Partner Outreach Finds That Many Acute Infections in North Carolina May Stem From Exposure to Chronically Infected Patients

There's nothing like hearing the results of studies directly from those who actually conducted the research. It is these women and men who are transforming HIV treatment and care. In this interview, you'll meet one of these impressive HIV researchers...